Study to Assess the Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation Following Cataract Surgery
Latest Information Update: 04 Sep 2020
At a glance
- Drugs Mapracorat (Primary)
- Indications Postoperative inflammation; Postoperative pain
- Focus Therapeutic Use
- Sponsors Bausch & Lomb
Most Recent Events
- 23 Dec 2014 New trial record